DGPharma
ActiveSummary
DGPharma has been active since 2012 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €300,586 and a net result of €158,798. Equity is growing by about 13% per year across the filed financial years. Its solvency ranks better than 34% of 12,519 sector peers (NACE 47, financial year 2025). The computed 12-month bankruptcy probability is 0.8% (low).
Directors
Owners and capital
Owners
1 ownerChain of control
- Ceres Invest
- Ceres Pharma
- CREDOPHAR
- Labophar
- DGPharma
Highest known parent: Ceres Invest. The sources do not say who stands above it.
Owners 1
- LabopharparentSourceaccounts Labophar 2025100%
Sources: the companies' annual accounts, the acts in the Belgian Official Gazette and the LEI register. Annual accounts state the shareholders that notified the company under article 7:225 of the Code of Companies and Associations and the parent companies that consolidate it. The register of ultimate beneficial owners (UBO) is not public: who ultimately stands behind a natural person or a foreign parent is not stated here. A company that does not include these statements in its annual accounts, or does not have to, is not listed.